Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

NexImmune, Inc. NEXI OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
65/100
4/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$3.33
+3329900%

NexImmune, Inc. (NEXI) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 63/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is NEXI = $3 (+3329900% upside).

Net income is $32M (loss), growing at +307.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $68,809 against $4M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 1.06 (adequate). Debt-to-assets is 0.8%. Total assets: $9M.

Analyst outlook: 2 / 4 analysts rate NEXI as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 75/100 (Pass), Moat 28/100 (Fail), Future 64/100 (Pass), Income ?/100 (Fail).

$3.33
▲ 3329900% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for NexImmune, Inc., the average price target is $3.33, with a high forecast of $5.00, and a low forecast of $2.00.
Highest Price Target
$5.00
Average Price Target
$3.33
Lowest Price Target
$2.00

NEXI SharesGrow Score Overview

65/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NEXI

✓
VALUE Pass
100/100
NEXI trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $3, implying +2999900% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
NEXI: +0%/yr revenue is, +307.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
NEXI: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
75/100
Balance sheet NEXI: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 1.06 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
NEXI: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 2 / 4 analysts rate NEXI as buy (50%). Analyst consensus target is $3 (+2999900% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.0001-1.01
Volume100
Avg Volume (30D)35
Market Cap$139.00
Beta (1Y)5.47
Share Statistics
EPS (TTM)-30.82
Shares Outstanding$1.05M
IPO Date2021-02-12
Employees6
CEOJohn Trainer
Financial Highlights & Ratios
Gross Profit$-1.02M
EBITDA$-28.17M
Net Income$-32.34M
Operating Income$-29.19M
Total Cash$4.65M
Total Debt$68.81K
Net Debt$-3.13M
Total Assets$8.59M
Price / Earnings (P/E)-0
Analyst Forecast
1Y Price Target$3.00
Target High$5.00
Target Low$2.00
Upside+2,999,900.0%
Rating ConsensusBuy
Analysts Covering4
Buy 50% Hold 50% Sell 0%
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS65344D2080

Price Chart

Track all markets on TradingView
NEXI
NexImmune, Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
0.00 52WK RANGE 1.01

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 PALI
PALI
Palisade Bio, Inc.
$2.06
+3.52%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 UNCY
UNCY
Unicycive Therapeutics, Inc.
$6.94
+4.83%
 LABP
LABP
Landos Biopharma, Inc.
$22.93
+0.57%
 PDSB
PDSB
PDS Biotechnology Corporation
$1.06
-2.75%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message